Please try another search
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Name | Age | Since | Title |
---|---|---|---|
Fred M. Schwarzer | 70 | 2003 | CEO, President & Director |
Christina Teng Topsoe | 42 | 2018 | Independent Director |
Julie Hambleton | 65 | 2018 | Independent Director |
Jakob Haldor Topsoe | 54 | 2018 | Independent Director |
Felix James Baker | 54 | 2021 | Independent Director |
Michael Stewart Lee | 44 | 2019 | Independent Director |
M. Kathleen Behrens | 71 | 2019 | Independent Director |
William Strohl | 70 | 2018 | Independent Director |
Mark M. Davis | - | - | Member of Scientific Advisory Board |
Gordon J. Freeman | - | - | Member of Scientific Advisory Board |
Elizabeth H.Z. Thompson | 48 | 2023 | Director |
Rafi Ahmed | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review